Gastrointestinal stromal tumors: a paradigm for molecularly targeted therapy.
von Mehren
Margaret
M
Fox Chase Cancer Center, Dept. of Medical Oncology, 7701 Burholme Ave., Philadelphia, PA 19111, USA.
D000970:Antineoplastic Agents / Q000494:pharmacology*; D001549:Benzamides; D005770:Gastrointestinal Neoplasms / Q000235:genetics* / Q000473:pathology* / Q000628:therapy; D015316:Genetic Therapy; D006801:Humans; D000068877:Imatinib Mesylate; D015994:Incidence; D010879:Piperazines / Q000494:pharmacology*; D011379:Prognosis; D011505:Protein-Tyrosine Kinases / Q000235:genetics* / Q000494:pharmacology*; D019009:Proto-Oncogene Proteins c-kit / Q000235:genetics* / Q000494:pharmacology*; D011743:Pyrimidines / Q000494:pharmacology*; D017154:Stromal Cells / Q000473:pathology*
D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate; D011505:Protein-Tyrosine Kinases; D019009:Proto-Oncogene Proteins c-kit